U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   FORM 10-QSB
                                   (Mark One)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 for the quarterly period ending September 30, 2006


[_]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934

                 For the transition period from _____to_____


                         Commission file number 0-30520


                        GLOBAL IMMUNE TECHNOLOGIES, INC.
                 ----------------------------------------------
                 (Name of Small Business Issuer in its Charter)


             WYOMING
      ----------------------              ---------------------------------
     (State of Incorporation)             (IRS Employer identification No.)


1518 West Hastings St., Vancouver, B.C. Canada                     V6G 3J4
----------------------------------------------                   ----------
    (Address of principal executive offices)                     (Zip Code)


1518 West Hastings St., Vancouver, B.C. Canada                     V6G 3J4
----------------------------------------------                   ----------

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Applicable  only to  issuers  involved  in  bankruptcy  proceedings  during  the
preceding five years

Check whether the  registrant  filed all  documents  and reports  required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the  distribution  of
securities under a plan confirmed by a court. Yes [X] No [ ]

Indicate by check mark whether the  registrant is a shell company (as defined by
Rule 12b-2 of the Exchange Act). Yes x  No
                                    ---   ---

Applicable on to corporate issuers
State the number of shares  outstanding  of each of the issuer's class of Common
equity, as of September 30, 2006: 190,195,645

Transitional Small Business Disclosure Format (Check One)Yes [ ] No [X]

<PAGE>

Table of Contents

Item 1.   Financial Statements.................................................2
          Balance Sheet unaudited).............................................3
          Statements of Operations unaudited)..................................4
          Statements of Cash Flows unaudited)..................................5
          Statement of Changes in Stockholders' Deficit........................6
          Notes to Financial Statements.....................................8-15

Item 2.   Management's Discussion and Analysis or Plan of
          Operation...........................................................16

Item 3.   Controls and Procedures.............................................26

PART II. OTHER INFORMATION

Item 1.   Legal Proceedings...................................................27

Item 2.   Unregistered Sale of Equity Securities and
          Use of Proceeds.....................................................27

Item 3.   Defaults upon Senior Securities.....................................27

Item 4.   Submission of Matters to a Vote
          of Security Holders.................................................27

Item 5.   Other Information...................................................28

Item 6.   Exhibits............................................................28

Signatures....................................................................28











                                      -1-
<PAGE>

                          PART I-FINANCIAL INFORMATION

Item 1.   Financial Statements




Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)

Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
























                                      -2-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Balance Sheets
(Expressed in Canadian Dollars)
(Unaudited)
-------------------------------------------------------------------------------

                                                        As at 30       As at 31
                                                       September     March 2006
                                                            2006      (Audited)
                                                               $              $

Assets

Current
Cash and cash equivalents                                      41           165
                                                       ----------    ----------

                                                               41           165
                                                       ----------    ----------

Liabilities

Current
Accounts payable and accrued liabilities (Note 3)          28,862       154,192
Due to related parties (Note 4)                           508,180       366,854
                                                       ----------    ----------

                                                          537,042       521,046
                                                       ----------    ----------

Stockholders' deficiency
Capital stock  (Note 6)
Authorized
  Unlimited common shares without par value
Issued and outstanding
  30 September 2006 - 190,195,645 common shares
  31 March 2006 - 116,195,645  common shares            4,990,523     4,990,523
Additional paid-in capital                                 43,500        30,000
Deficit                                                (5,571,024)   (5,541,404)
                                                       ----------    ----------

                                                         (537,001)     (520,881)
                                                       ----------    ----------

                                                               41           165
                                                       ----------    ----------


Nature and Continuance of Operations (Note 1) and Commitments (Note 10)


                                      -3-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statements of Operations
(Expressed in Canadian Dollars)
(Unaudited)
--------------------------------------------------------------------------------------------------

                                              For the        For the        For the        For the
                                          three month    three month      six month      six month
                                               period         period         period         period
                                             ended 30       ended 30       ended 30       ended 30
                                            September      September      September      September
                                                 2006           2005           2006           2005
                                                    $              $              $              $
<S>                                       <C>            <C>            <C>            <C>
Expenses
General and administrative (Schedule 1)        17,450         10,539         29,668         37,281
                                          -----------    -----------    -----------    -----------

Net loss before other items                   (17,450)       (10,539)       (29,668)       (37,281)

Other items
Foreign exchange gain                              48           --               48           --
Write off of loan receivable (Note 7)            --          (30,000)          --          (30,000)
                                          -----------    -----------    -----------    -----------

Net loss for the period                       (17,402)       (40,539)       (29,620)       (67,281)

Deficit, beginning of period               (5,553,622)    (5,456,227)    (5,541,404)    (5,429,485)
                                          -----------    -----------    -----------    -----------

Deficit, end of period                     (5,571,024)    (5,496,766)    (5,571,024)    (5,496,766)
                                          -----------    -----------    -----------    -----------

Basic and diluted loss per
common share                                    (0.01)         (0.01)         (0.01)         (0.01)
                                          -----------    -----------    -----------    -----------

Weighted average number of common
shares used in per share calculations      16,195,645     16,195,645     16,195,645     16,195,645
                                          -----------    -----------    -----------    -----------
</TABLE>








                                      -4-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statements of Cash Flows
(Expressed in Canadian Dollars)
(Unaudited)
------------------------------------------------------------------------------------------------------------

                                            For the three    For the three      For the six      For the six
                                             month period     month period     month period     month period
                                                    ended            ended            ended            ended
                                             30 September     30 September     30 September     30 September
                                                     2006             2005             2006             2005
                                                        $                $                $                $
<S>                                         <C>              <C>              <C>              <C>
Cash flows from operating activities
Net loss for the period                           (17,402)         (40,539)         (29,620)         (67,281)
   Adjustments to reconcile loss to net
   cash used by operating activities
      Contributions to capital by related
      party - expenses (Notes 5 and 9)              6,000            7,500           13,500           15,000
      Write-off of loan receivable (Note7)           --             30,000             --             30,000
Changes in operating assets and
liabilities
  Decrease in amounts receivable                     --               --               --             10,155
  Increase (decrease) in accounts payable
  (Notes 3 and 9)                                   8,339          (14,002)           7,395         (127,754)
                                            -------------    -------------    -------------    -------------

                                                   (3,063)         (17,041)          (8,725)        (139,880)
                                            -------------    -------------    -------------    -------------

Cash flows from financing activities
(Decrease) in bank indebtedness                    (1,896)          (3,089)            --               --
(Increase) in loan receivable (Note 7)               --            (30,000)            --            (30,000)
Increase  in due to related parties
(Notes 4 and 9)                                     5,000           60,012            8,601          179,762
                                            -------------    -------------    -------------    -------------

                                                    3,104           26,923            8,601          149,762
                                            -------------    -------------    -------------    -------------

Increase (decrease) in cash and cash
equivalents                                            41            9,882             (124)           9,882

Cash and cash equivalents, beginning of
period                                               --               --                165             --
                                            -------------    -------------    -------------    -------------

Cash and cash equivalents, end of period               41            9,882               41            9,882
                                            -------------    -------------    -------------    -------------
</TABLE>

Supplemental Disclosures with Respect to Cash Flows (Note 9)




                                      -5-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Statement of Changes in Stockholders' Deficiency
(Expressed in Canadian Dollars)
(Unaudited)
------------------------------------------------------------------------------------------------------------------------

                                     Number of      Capital Stock        Additional                        Stockholders'
                                 shares issued                      paid-in capital           Deficit         deficiency
                                                                $                 $                 $                  $
<S>                             <C>               <C>               <C>               <C>                <C>
Balance at 31 March 2004             16,195,645         4,980,523              --          (5,488,862)          (508,339)
  Net income for the year                  --                --                --              59,377             59,377
                                ---------------   ---------------   ---------------   ---------------    ---------------

Balance at 31 March 2005             16,195,645         4,980,523              --          (5,429,485)          (448,962)
  Shares issued in escrow
  (Note 6)                          100,000,000            10,000              --                --               10,000
  Contributions to capital by
  related party - expenses
  (Note 5)                                 --                --              30,000              --               30,000
  Net loss for the year                    --                --                --            (111,919)          (111,919)
                                ---------------   ---------------   ---------------   ---------------    ---------------

Balance at 31 March 2006            116,195,645         4,990,523            30,000        (5,541,404)          (520,881)
  Shares issued in escrow
  (Notes 6 and 10)                   74,000,000              --                --                --                 --
  Contributions to capital by
  related party - expenses
  (Note 5)                                 --                --              13,500              --               13,500
  Net loss for the period                  --                --                --             (29,620)           (29,620)
                                ---------------   ---------------   ---------------   ---------------    ---------------

Balance at 30 September 2006        190,195,645         4,990,523            43,500        (5,571,024)          (537,001)
                                ---------------   ---------------   ---------------   ---------------    ---------------
</TABLE>








                                      -6-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Schedule 1 - General and Administrative Expenses
(Expressed in Canadian Dollars)
(Unaudited)
---------------------------------------------------------------------------------------------------------

                                   For the three      For the three        For the six        For the six
                                    month period       month period       month period       month period
                                        ended 30           ended 30           ended 30           ended 30
                                  September 2006     September 2005     September 2006     September 2005
                                               $                  $                  $                  $
<S>                               <C>                <C>                <C>                <C>
Bank charges and interest                     92                 19                310                 44
Directors fees                                 -              2,000                  -              2,000
Investor relations                           449                  -                449                679
Legal and accounting fees                  5,940                  -             10,440             12,655
Management fees (Notes 5 and 9)            6,000              6,000             12,000             12,000
Office and administration                      -                  -                  -                465
Rent (Notes 5 and 9)                       1,000              1,500              2,500              3,000
Trust and filing fees                      3,969              1,020              3,969              6,438
                                  ---------------    ---------------    ---------------    ---------------

                                          17,450             10,539             29,668             37,281
                                  ---------------    ---------------    ---------------    ---------------
</TABLE>















                                      -7-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

1.   Nature and Continuance of Operations

     Global  Immune  Technologies  Inc.  (the  "Company")  (formerly  Secureview
     Systems Inc.) was  incorporated  on 18 September 1985 in British  Columbia,
     Canada.  During the six month period  ended 30  September  2006 the company
     applied for  voluntary  dissolution  in British  Columbia  and  articles of
     continuance  in the state of Wyoming.  The Company  was  organized  for the
     purpose of exploring mineral properties.

     The  Company's  financial  statements  as at 30 September  2006 and for the
     three and six month  periods  then  ended  have  been  prepared  on a going
     concern  basis,  which  contemplates  the  realization  of  assets  and the
     settlement of liabilities and commitments in the normal course of business.
     The  Company  has a loss of  $29,620  for the six  month  period  ended  30
     September  2006 (30  September  2005 - $67,281)  and has a working  capital
     deficiency of $537,001 at 30 September 2006 (31 March 2006 - $520,881).

     Management  cannot  provide  assurance  that the  Company  will  ultimately
     achieve  profitable  operations  or  become  cash flow  positive,  or raise
     additional  debt  and/or  equity  capital.  Management  believes  that  the
     Company's  capital  resources should be adequate to continue  operating and
     maintaining  its business  strategy  during the fiscal year ending 31 March
     2007.  However, if the Company is unable to raise additional capital in the
     near future,  due to the Company's  liquidity  problems  management expects
     that the Company will need to curtail  operations,  liquidate assets,  seek
     additional  capital on less  favorable  terms and/or pursue other  remedial
     measures. These financial statements do not include any adjustments related
     to the  recoverability  and  classification  of assets or the  amounts  and
     classification of liabilities that might be necessary should the Company be
     unable to continue as a going concern.

     Management is currently  attempting to implement its business  plan, and is
     seeking additional sources of equity or debt financing, however there is no
     assurance  these  activities will be successful.  Accordingly,  the Company
     must  rely  on  its  president  to  perform  essential   functions  without
     compensation  until a business  operation can be  commenced.  These factors
     raise  substantial  doubt about the ability of the Company to continue as a
     going concern. The financial statements do not include any adjustments that
     might result from the outcome of this uncertainty.

2.   Significant Accounting Policies

     The following is a summary of significant  accounting  policies used in the
     preparation of these financial statements.

     Basis of presentation

     The accompanying  unaudited interim financial statements have been prepared
     as at 30 September 2006 and for the three and six month periods then ended,
     in accordance with accounting  principles  generally accepted in the United
     States of America  relating to the preparation of financial  statements for
     interim periods.  Accordingly,  they do not include all the information and
     footnotes required by generally accepted accounting principles for complete
     financial  statements.  In  the  opinion  of  management,  all  adjustments
     (consisting of normal recurring accruals)  considered  necessary for a fair
     presentation  have been included.  Operating  results for the three and six


                                      -8-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     months period ended 30 September 2006 are not necessarily indicative of the
     results that may be expected for the year ending 31 March 2007.

     These interim financial  statements follow the same accounting policies and
     methods  of  their   application  as  the  most  recent  annual   financial
     statements,  except as noted  below.  These  interim  financial  statements
     should be read in conjunction with the audited financial  statements of the
     Company as at 31 March 2006.

     Cash and cash equivalents

     Cash and cash equivalents  include highly liquid  investments with original
     maturities of three months or less.

     Financial instruments

     The carrying value of cash, accounts payable and accrued  liabilities,  and
     due to related parties  approximates  their fair value because of the short
     maturity of these  instruments.  Unless otherwise noted, it is management's
     opinion that the Company is not exposed to significant  interest,  currency
     or credit risk arising from these financial instruments.

     Derivative financial instruments

     The  Company has not, to the date of these  financial  statements,  entered
     into  derivative  instruments  to offset  the  impact of  foreign  currency
     fluctuations.

     Income taxes

     Future income tax assets and liabilities are determined  based on temporary
     differences  between  the  accounting  and the tax bases of the  assets and
     liabilities  and for loss carry  forwards,  and are measured  using the tax
     rates  expected  to apply  when  these  differences  reverse.  A  valuation
     allowance is recorded against any future income tax asset if it is not more
     likely than not that the asset will be realized.  As at 30 September  2006,
     the  Company's net future income tax assets are fully offset by a valuation
     allowance.

     Basic and diluted net loss per share

     Basic loss per share is calculated  based on the weighted average number of
     shares outstanding during the period. The treasury stock method is used for
     determining   the  dilutive  effect  of  options  and  warrants  issued  in
     calculating  diluted  earnings per share.  Under this method,  the dilutive
     effect  on loss per share is  recognized  on the use of the  proceeds  that
     could be  obtained  upon the  exercise  of  options,  warrants  and similar
     instruments.  It assumes that the proceeds would be used to purchase common
     shares  at the  average  market  price  during  the  year.  For  the  years
     presented, this calculation proved to be anti-dilutive.

     Foreign currency translation

     The Company's  functional  and reporting  currency is in Canadian  dollars.
     Monetary  assets and  liabilities  denominated  in foreign  currencies  are
     translated  into Canadian  dollars at the rate of exchange in effect at the


                                      -9-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     balance sheet date. Non-monetary assets and liabilities are translated into
     Canadian  dollars  at  their  applicable  historical  rates.  Revenues  and
     expenses are translated at rates  prevailing at the date of the transaction
     except for amortization,  which is translated at historical rates. Exchange
     gains and losses from the translation of foreign  currencies are recognized
     in the period in which they occur.

     Use of estimates

     The  preparation  of financial  statements  in conformity  with  accounting
     principles  generally  accepted  in the United  States of America  requires
     management  to make  estimates and  assumptions  that affect the amounts of
     assets and liabilities and disclosures of contingent assets and liabilities
     at the  date of the  financial  statements  and  the  reported  amounts  of
     revenues and expenditures during the reporting period. Actual results could
     differ from these estimates.

     Comparative figures

     Certain  comparative  figures have been  adjusted to conform to the current
     period's presentation.

3.   Accounts Payable and Accrued Liabilities

     Accounts  payable  and  accrued   liabilities  are  non-interest   bearing,
     unsecured and have settlement dates within one year.

4.   Due to Related Parties

     As at 30  September  2006,  the  amount due to related  party  includes  of
     $74,639  (31  March  2006  -  $54,539)   payable  to  a   shareholder   and
     officer-director of the Company (Note 5).

     As at 30  September  2006,  the  amount due to related  party  includes  of
     $44,988 (31 March 2006 - $44,987)  payable to a shareholder  of the Company
     (Note 5).

     As at 30 September 2006, the amount due to related party includes  $388,553
     (31 March 2006 - $267,328)  payable to a  shareholder  of the Company (Note
     5).

     Amounts due to related parties are non-interest bearing, unsecured and have
     no fixed terms of repayment.

5.   Related Party Transactions

     During the six month period ended 30 September  2006,  the Company  entered
     into the following transactions with related parties:

     (a)  Officers-directors,   and  their   controlled   entities,   have  made
          contributions to capital for management fees and rent in the amount of
          $12,000 (30 September  2005 - $12,000) and $1,500 (30 September 2005 -
          $3,000) respectively (Note 9).


                                      -10-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     (b)  An amount of $11,500  was paid by a director  and  shareholder  of the
          Company to settle outstanding accounts payable balances (Note 9).

     (c)  An amount of  $121,225  was paid by a  shareholder  of the  Company to
          settle outstanding accounts payable balances (Note 9).

6.   Capital Stock

     Authorized

     In May  2005,  the  Company  altered  its  authorized  capital  stock  from
     100,000,000  common shares to an unlimited  number of common shares without
     par value.

     Issued and outstanding

     The total issued and outstanding capital stock is 190,195,645 common shares
     without a par value.

     During the year ended 31 March 2006, the Company  proceeded with a proposed
     acquisition  of the rights to the drug  Trioxolane.  Under the terms of the
     transaction,  the Company issued  100,000,000 common shares in trust, which
     were  held in escrow  subject  to  completion  of the  acquisition.  As the
     transaction was not completed,  the common shares were returned to treasury
     of  the  Company  and  the  Company  is in the  process  of  canceling  the
     certificates.

     During three month period ended 30 September 2006, the Company entered into
     a securities  exchange  agreement (the  "Agreement")  with MediPri  Limited
     ("MedPri"),  Primedical  International  Ltd. ("PML"),  and Medical Monitors
     Limited  ("MML").  Under the terms of the  agreement,  the  Company  issued
     74,000,000  common  shares  in trust on 8 August  2006,  which  are held in
     escrow subject to the completion of the Agreement (Note 10).

     Escrow Shares

     A total of 100,000,000  common shares of the Company were held in escrow by
     the Company at 30 September 2006 pending cancellation.

     A total 74,000,000  common shares of the Company were held in escrow by the
     Company  at  30  September  2006  subject  to  potential  completion  of  a
     securities exchange agreement (Note 10).





                                      -11-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     Share purchase warrants

     The following  share  purchase  warrants were  outstanding  at 30 September
     2006:

                                                                      Remaining
                                                      Number   contractual life
                                Exercise price   of warrants            (years)
                                             $

       Warrants (Note 9)                  0.03     2,500,000               1.19
                                                 -----------

                                                   2,500,000
                                                 -----------

     A summary of outstanding share purchase warrants is as follows:

                                                          Number of    Weighted
                                                              share     average
                                                           purchase    exercise
                                                           warrants       price
                                                                              $

       Outstanding and exercisable at 1 April 2006        2,500,000        0.03

       Granted                                                 --
       Exercised                                               --
       Forfeited                                               --
       Cancelled                                               --
                                                          ---------   ---------

       Outstanding and exercisable at 30 September 2006   2,500,000        0.03
                                                          ---------   ---------

     Stock options

     Under the  Company's  stock option plan,  the Company may grant  options to
     employees,  officers,  and  directors  for the purchase of its common stock
     from  treasury.  The  aggregate  number of shares so reserved  for issuance
     shall  not  exceed  10% of the  issued  and  outstanding  shares,  and  the
     aggregate  number of shares so reserved for issuance to any one  individual
     shall not exceed 5% of the issued and outstanding  shares.  Under the plan,
     the options are exercisable  upon issuance and an option's  maximum term is
     five years.


                                      -12-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

                                                          30 September      30 September
                                                                  2006              2005
                                                                     $                 $
<S>                                                       <C>               <C>
       Outstanding and exercisable at 1 April 2006                 --            427,729

       Granted                                                     --               --
       Exercised                                                   --               --
       Forfeited                                                   --               --
       Cancelled                                                   --           (427,729)
                                                          -------------     ------------

       Outstanding and exercisable at 30 September 2006            --               --
                                                          -------------     ------------
</TABLE>

7.   Loan Receivable

     During  the year ended 31 March  2006,  the  Company  loaned  $30,000  cash
     pursuant  to an  agreement  dated  23  September  2005  to  Global  Lottery
     Corporation,  a Nevada corporation.  The terms of the agreement stated that
     the  Company  shall have the option to convert  this  promissory  note into
     shares of common stock of Global Lottery  Corporation on the basis of $0.10
     per share. Collection is doubtful and the balance has been offset by a full
     valuation allowance as at 30 September 2005.

8.   Income Taxes

     Provision for income taxes

     The  provision  for (recovery of) income taxes differs from the amount that
     would have resulted by applying  Canadian federal and provincial  statutory
     tax rates of 34.0% (30 September  2005 - 35.6%) to net loss for the periods
     as follows:

                                                    For the six    For the six
                                                   month period   month period
                                                       ended 30       ended 30
                                                      September      September
                                                           2006           2005
                                                              $              $

Net loss before income taxes                            (29,620)       (67,281)
                                                   ------------   ------------

Income tax recovery at statutory rates                   10,071         23,952
Adjustments to benefits resulting from:
   Contributions to capital by related party             (4,590)        (5,340)
   (Unrecognized) benefits of non-capital losses         (5,481)       (18,612)
                                                   ------------   ------------

Future income tax recovery (liability)                     --             --
                                                   ------------   ------------


                                      -13-
<PAGE>
<TABLE>
<CAPTION>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     Future tax balances

     As at 30 September 2006, the Company has accumulated  operating  losses for
     income  tax  purposes  of  approximately  $1,478,261  which may be  carried
     forward to reduce taxable income of future years. The potential tax benefit
     of these losses has not been reflected in the financial statements as it is
     more likely  than not that these  losses  will not be  utilized.  They will
     expire at various  dates to 30 September  2016.  The  potential  income tax
     benefit of these losses has been offset by a full valuation allowance.

9.   Supplemental Disclosures with Respect to Cash Flows

                                                       For the three   For the three
                                                        month period    month period
                                                               ended           ended
                                                        30 September    30 September
                                                                2006            2005
                                                                   $               $
<S>                                                    <C>             <C>
       Cash paid during the period for interest                 --              --
       Cash paid during the period for income taxes             --              --
</TABLE>

     During the six month period ended 30  September  2006,  officers-directors,
     and their  controlled  entities,  have made  contributions  to capital  for
     management  fees and rent in the amount of  $12,000  (30  September  2005 -
     $12,000) and $1,500 (30 September 2005 - $3,000) respectively (Note 5).

     During the six month period ended 30 September  2006,  an amount of $11,500
     was paid by a director and shareholder of the Company to settle outstanding
     accounts payable balances (Note 5).

     During the six month period ended 30 September  2006, an amount of $121,225
     was paid by a  shareholder  of the Company to settle  outstanding  accounts
     payable balance (Note 5).

10.  Commitments

     The following commitments are outstanding as at 30 September 2006:

     1)   As at 30  September  2006,  the  Company had  outstanding  warrants to
          purchase 2,500,000 shares of the Company's common shares at a price of
          $0.03 per share. The warrants became exercisable in 2004 and expire at
          various dates through 2007. At 30 September 2006,  2,500,000 shares of
          common stock were reserved for that purpose.

     2)   On 4  July  2006  the  Company  entered  into  a  securities  exchange
          agreement  (the   "Agreement")   with  MediPri   Limited   ("MedPri"),
          Primedical  International  Ltd. ("PML"),  and Medical Monitors Limited
          ("MML").  Under the  Agreement,  the  Company  shall  issue to PML the
          following securities:


                                      -14-
<PAGE>

Global Immune Technologies Inc.
(Formerly Secureview Systems Inc.)
Notes to Financial Statements
(Expressed in Canadian Dollars)
(Unaudited)
30 September 2006
--------------------------------------------------------------------------------

     i.   A total of 74,000,000  common  shares of the Company  (issued 8 August
          2006).

     ii.  A total of  7,400,000  share  purchase  warrants  where  each  warrant
          represents  the right to purchase one common share of the Company at a
          price of  $0.50USD  for a period  of five  years  from the date of the
          Agreement.

     iii. A promissory note in the amount of $10,000,000  payable  automatically
          and  without  demand  on the  third  anniversary  of the  date  of the
          Agreement.  This  promissory  note is to be  non-interest  bearing and
          convertible  into common shares of the Company at the holder's  option
          at any time prior to the maturity date, the conversion amount is to be
          at a price equal to eighty-five  percent of the average  closing price
          of the Company's common shares over the five business days immediately
          preceding the date of the conversion. At no time shall such conversion
          price be less than $0.40USD or greater than $1.00USD.

     iv.  A  promissory  note issued to MML in  consideration  for  intellectual
          property,   bearing  no   interest,   in  the   principle   amount  of
          $4,000,000USD,  payable  automatically and without demand on the first
          anniversary  of the  date  of  this  agreement.  Such  note  shall  be
          convertible  into common shares of the Company at the holder's  option
          at any time prior to the maturity  date,  such  conversion  to be at a
          price equal to eighty-five percent of the average closing price of the
          Company's  common shares over the immediately  preceding five business
          days. At no time shall such conversion  price be less than $0.40USD or
          greater than $1.00USD.

     In exchange for the issuance by the Company to PML of the Company's shares,
     warrants,  and promissory notes, PML shall assign and convey to the Company
     all of its interest in  58,302,000  shares of common stock of MedPri.  Such
     shares are to constitute all of the outstanding capital stock of MedPri.












                                      -15-
<PAGE>

Item 2.   Management's Discussion and Analysis or Plan of Operation.

FORWARD-LOOKING STATEMENT NOTICE:

This quarterly  report on Form 10-QSB and our future filings with the Securities
and Exchange Commission contain many forward-looking  statements,  which involve
risks and  uncertainties.  For this purpose,  any  statements  contained in this
report  that  are  not  statements  of  historical  fact  may  be  deemed  to be
forward-looking statements.  Without limiting the foregoing,  statements such as
our plans,  objective,  expectations  and  intentions.  You can  identify  these
statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could,"  "estimate,"  "continue,"  "plans," or other similar words or
phrases.  Some of these  statements  include  discussions  regarding  our future
business strategy and our ability to generate revenue, income, and cash flow.

These statements are intended to identify forward-looking  statements within the
meaning of the various  securities  acts. We wish to caution the reader that all
forward-looking  statements contained in this Form 10-QSB are only estimates and
predictions.  Our actual results could differ  materially from those anticipated
as a result of risk facing us or actual events  differing  from the  assumptions
underlying such forward-looking  statements.  Readers are cautioned not to place
undue  reliance on any  forward-looking  statements  contained in this Quarterly
Report on Form  10-QSB.  Readers are  cautioned  not to place undue  reliance on
these  forward-looking  statements.  We undertake no obligation to update any of
these  factors  or to  publicly  announce  any  change  to  our  forward-looking
statements made herein,  whether as a result of new information,  future events,
changes in expectations or otherwise.

Overview

     (a)  Our Corporate History.
          ---------------------

The  Company was  incorporated  on  September  18,  1985,  under the laws of the
Province of British  Columbia  under the name of Canadian  Comstock  Exploration
Ltd. with an authorized share capital of 20,000,000 shares without par value.

The Company  changed its name on June 7, 1995 to American  Comstock  Exploration
Ltd. in connection with a  consolidation  of its share capital on a one for four
basis.

The  Company  changed  its name  again on  February  4,  1998 to  "International
Comstock  Exploration  Ltd." in  connection  with a  consolidation  of its share
capital on a one for five basis.

The  Company  changed its name again on October 2, 2001 to  "Secureview  Systems
Inc." in connection with a consolidation  of its share capital on a one for five
basis.  In addition,  the Company  increased  its  authorized  share  capital to
100,000,000 shares without par value on October 2, 2001.

The Company changed its name again on May 2, 2005 to "Global Immune Technologies
Inc." In addition,  the Company  increased  its  authorized  share capital to an
unlimited number of common shares without par value on March 23, 2005.

On February 28, 2006,  the Company  changed its corporate  domicile from British
Columbia, Canada to the State of Wyoming.

     (b)  Business History of the Issuer.
          ------------------------------

     From its  incorporation  in 1985 until 1999, the Company was engaged in the
business of exploration of natural resource properties.  During 2004 the Company
disposed of its final  interests in its natural  resource  properties.  In early
1999 the Company initiated a search for other business opportunities culminating
in May 1999  with the  acquisition  of the  domain  name  ProSportsPool.com.  In


                                      -16-
<PAGE>

January 2000, the Company entered into an agreement with Internet Sports Network
Inc. to develop  and  maintain a number of  internet  based games and  contests.
Internet Sports Network eventually developed "Fantasy Free for All" software and
back end support for Nascar,  Formula  One,  Cart series and Baseball and Hockey
contests  for  ProSportsPool.com.  The  Company  launched  the  ProSportsool.com
website on March 1, 2000 with Formula 1 and NASCAR  contests  "Fantasy  Free for
All".  The launch of the website was  accompanied  by a marketing  campaign that
included print, billboard, and internet-banner  advertising.  In March 21, 2000,
the Company  engaged  Iceberg  Media.com  Inc. to provide three music channels -
1Groove.com,  2Kool4Radio.com  and  PrimeTicket.net - for the  ProSportsPool.com
website. The ProSportsPool.com  website added a fantasy baseball contest, and an
affiliation  with  Altavista.com  on March 27, 2000.  At the  beginning of April
2000,  the Company  launched its internet based hockey contest and announced its
inaugural  contest  winners  in  its  auto-racing  contests.  The  Company  also
announced it has become an authorized  member of the Cnet.com  affiliate network
and formed similar affiliations with Chipshot.com, Wrenchead.com, Quokka.com and
America Online.

     To  increase  awareness  of  the  ProSportspool.com  website,  the  Company
participated  at the G.I. Joe 200 CART race in  Portland,  Oregon as well as the
Toronto and Vancouver Indy races by appearing at a booth at the races signing up
contestants  and offering  prizes to entrants.  On January 15, 2001,  due to the
closing  of  Internet   Sports  Network  Inc.,   which  provided  the  technical
architecture and sports data for the  ProSportsPool.com's  sports contests,  the
Company was forced to discontinue its sports-contest site.

     During  June 2001 and amended  October,  2001 the  Company  entered  into a
letter of intent with Argent Resources Ltd.,  On-Track  Computer  Training Ltd.,
On-Track  Computer  International  Ltd. and Lute Linux.com Corp.  whereby Argent
assigned its right to enter into a share  exchange  agreement with Lute who held
the option to enter into a share  exchange  agreement with On-Track and On-Track
International.  In exchange for the  assignment  by Argent to the Company of the
share  exchange  agreement  entered into  between  Lute and Argent,  the Company
issued 2,000,000 shares and paid $50,000 to Argent.

     During  October 2001 the Company  signed an agreement  with Lute  Linux.com
Corp.  including the exchange of Lute share purchase warrants for Company shares
at a deemed value of $0.10 US per share, as to Russ Rossi (100,000 shares), RRGS
Creative  Management Corp.  (2,400,000  shares) and Quest Ventures Ltd. (175,000
shares). The Company did not proceed with similar share purchase agreements with
On-Track Computer Training Ltd. and On-Track  Computer  International  Ltd. Lute
focused  its  business  development  on  its  "Fedcam,"  an  inexpensive  remote
monitoring  system that allows  subscribers  to view their target  locations via
secure  website.  The  Fedcam  was  being  tested by the  Canadian  government's
construction  branch on its Osoyoos,  British Columbia border crossing site into
the United States. However, as of March 31, 2003, the Company ceased funding the
Fedcam and the asset was written down to a nominal amount.

     In June 2002 the  Company  entered  into a letter of  intent  with  Estwind
Energy, a private power generation company incorporated in Estonia,  whereby the
Company intended to acquire all of the issued and outstanding  shares of Estwind
Energy.  However,  the Company  decided  against  completing  the share exchange
agreement as the business of Estwind Energy was deemed to not be profitable.


                                      -17-
<PAGE>

     In May  2003  the  Company  entered  into a  letter  of  intent  with  P-CE
Computers,  Inc.,  a private  Nevada  corporation  engaged  in the  business  of
developing  ergonomic  multimedia-computer  workstations.  The  Company  decided
against completing the share exchange agreement as due diligence  indicated that
the business of P-CE Computers, Inc. would not be profitable.

     In  September  2003 the  Company  entered  into a letter of intent with TNR
Resources Ltd.  ("TNR"),  a public British  Columbia,  Canada,  corporation,  to
purchase a 50% working interest in TNR's Las Carachas property in Argentina. The
Company did not pursue the option.

     In February 2005 the Company entered an agreement to acquire the rights and
interests  in a drug,  Trioxolane.  The Company did not pursue or complete  this
acquisition.

     Subsequently  to March 31,  2005,  the Company  has agreed to purchase  WSG
Systems Inc.,  ("WSG") its' business and assets from Global Lottery  Corporation
for the  issuance  of  100,000,000  shares of common  stock.  The  assets of WSG
include  proprietary  technology,  software,  its trade names and  trademarks as
those  products  pertain to the  worldwide  lottery  industry  and/or  worldwide
pari-mutual betting. The products are designed to be used by all entities in the
industry  for  conducting  lotteries  and  or  pari-mutual  betting,   including
corporations and/or governmental  agencies  representing  countries,  provinces,
states,  etc. to implement  and/or to improve their lottery  and/or  pari-mutual
betting systems.

     On July 19, 2006, the Company entered into a securities  exchange agreement
with MediPri Limited,  Primemedical  International,  Ltd.("MedPri")  and Medical
Monitors  Limited  ("MML).   The  transaction  is  pending  subject  to  various
performance obligations of the parties.

     (c)  Current Business of the Issuer
          ------------------------------

     The Company may be referred to as a shell  corporation.  Shell corporations
are  defined as  companies  with no or nominal  assets and  operations.  Private
companies  wishing to become publicly  trading may wish to merge with a shell (a
reverse  merger)  whereby the  shareholders  of the private  Company  become the
majority of the  shareholders of the combined  Company.  The private Company may
purchase for cash all or a portion of the common shares of the shell corporation
from its major  stockholders.  Typically,  the Board and officers of the private
Company become the new Board and officers of the combined  Company and often the
name of the private Company becomes the name of the combined Company.

     The Company has very limited  capital,  and it is unlikely that the Company
will be able to take advantage of more than one such business  opportunity.  The
Company intends to seek  opportunities  demonstrating the potential of long-term
growth as opposed to short-term  earnings.  However,  at the present  time,  the
Company has not identified any business opportunity that it plans to pursue, nor
has the Company  reached any  agreement  or  definitive  understanding  with any
person concerning an acquisition.

     No assurance can be given that the Company will be successful in finding or
acquiring a desirable  business  opportunity,  given the limited  funds that are


                                      -18-
<PAGE>

expected to be available  for  acquisitions.  Furthermore,  no assurance  can be
given  that  any  acquisition,  which  does  occur,  will be on  terms  that are
favorable to the Company or its current stockholders.

     The  Company's  search  will be  directed  toward  small  and  medium-sized
enterprises,  which have a desire to become  public  corporations.  In  addition
these  enterprises  may wish to satisfy,  either  currently or in the reasonably
near future,  the minimum tangible asset  requirement in order to qualify shares
for trading on NASDAQ or on an exchange  such as the  American  Stock  Exchange.
(See  Investigation  and  Selection  of  Business  Opportunities).  The  Company
anticipates that the business  opportunities  presented to it will (i) either be
in the process of formation,  or be recently  organized  with limited  operating
history or a history of losses  attributable  to  under-capitalization  or other
factors; (ii) experiencing financial or operating difficulties; (iii) be in need
of funds to develop new products or services or to expand into a new market,  or
have plans for rapid expansion through acquisition of competing businesses; (iv)
or other  similar  characteristics.  The  Company  intends  to  concentrate  its
acquisition  efforts  on  properties  or  businesses  that  it  believes  to  be
undervalued  or that it believes  may realize a  substantial  benefit from being
publicly  owned.  Given the above  factors,  investors  should  expect  that any
acquisition  candidate may have little or no operating history,  or a history of
losses or low profitability.

     The  Company  does not  propose  to  restrict  its  search  for  investment
opportunities  to  any  particular  geographical  area  or  industry,  and  may,
therefore,  engage in  essentially  any  business,  to the extent of its limited
resources. This includes industries such as service, finance, natural resources,
manufacturing, high technology, product development, medical, communications and
others. The Company's  discretion in the selection of business  opportunities is
unrestricted,  subject  to the  availability  of  such  opportunities,  economic
conditions, and other factors.

     In connection with such a merger or  acquisition,  it is highly likely that
an amount of stock constituting control of the Company would either be issued by
the Company or be  purchased  from the  current  principal  stockholders  of the
Company by the acquiring  entity or its  affiliates.  If stock is purchased from
the  current  principal  stockholders,  the  transaction  is likely to result in
substantial  gains  to the  current  principal  stockholders  relative  to their
purchase price for such stock. In the Company's  judgment,  none of the officers
and directors  would  thereby  become an  underwriter  within the meaning of the
Section  2(11)  of the  Securities  Act of  1933,  as  amended  as  long  as the
transaction  is a  private  transaction  rather  than a public  distribution  of
securities. The sale of a controlling interest by certain principal shareholders
of the Company  would occur at a time when minority  stockholders  are unable to
sell their shares because of the lack of a public market for such shares.

     Depending  upon the nature of the  transaction,  the current  officers  and
directors of the Company may resign their  management  and board  positions with
the Company in connection  with a change of control or acquisition of a business
opportunity  (See  Form  of  Acquisition,   below).  In  the  event  of  such  a


                                      -19-
<PAGE>

resignation,  the Company's current  management would thereafter have no control
over the conduct of the Company's business.

     It is anticipated  that business  opportunities  will come to the Company's
attention from various sources,  including its officers and directors, its other
stockholders,   professional   advisors  such  as  attorneys  and   accountants,
securities  broker-dealers,   venture  capitalists,  members  of  the  financial
community,  and others who may present unsolicited proposals. The Company has no
plan,  understandings,  agreements,  or commitments with any individual for such
person to act as a finder of opportunities for the Company.

     The  Company  does  not  foresee  that  it  will  enter  into a  merger  or
acquisition  transaction  with any business with which its officers or directors
are currently affiliated.  Should the Company determine in the future,  contrary
to the forgoing  expectations,  that a transaction with an affiliate would be in
the best  interests  of the  Company  and its  stockholders,  the Company is, in
general,  permitted by Wyoming law to enter into a transaction  if: The material
facts as to the relationship or interest of the affiliate and as to the contract
or  transaction  are disclosed or are known to the Board of  Directors,  and the
Board in good faith authorizes, approves or ratifies the contract or transaction
by the  affirmative  vote of a majority  of the  disinterested  directors,  even
though  the  disinterested  directors  constitute  less  than a  quorum;  or the
material facts as to the relationship or interest of the affiliate and as to the
contract or transaction are disclosed or are known to the stockholders  entitled
to vote thereon,  and the contract or  transaction is  specifically  authorized,
approved or ratified in good faith by vote of the stockholders;  or the contract
or  transaction  is  fair as to the  Company  as of the  time it is  authorized,
approved or ratified, by the Board of Directors or the stockholders.

     (1)  Investigation and Selection of Business Opportunities

     To a large  extent,  a  decision  to  participate  in a  specific  business
opportunity may be made upon  management's  analysis of the quality of the other
Company's  management  and  personnel,  the  anticipated  acceptability  of  new
products  or  marketing  concepts,  the  merit  of  technological  changes,  the
perceived benefit the business  opportunity will derive from becoming a publicly
held entity, and numerous other factors which are difficult,  if not impossible,
to analyze through the application of any objective criteria. In many instances,
it  is  anticipated  that  the  historical  operations  of a  specific  business
opportunity  may not  necessarily  be indicative of the potential for the future
because of a variety of factors,  including,  but not  limited to, the  possible
need  to  expand  substantially,  shift  marketing  approaches,  change  product
emphasis,  change or  substantially  augment  management,  raise capital and the
like.

     It is anticipated that the Company will not be able to diversify,  but will
essentially be limited to the acquisition of one business opportunity because of
the Company's limited financing.  This lack of  diversification  will not permit
the Company to offset  potential  losses from one business  opportunity  against
profits from another,  and should be considered an adverse factor  affecting any
decision to purchase the Company's securities.


                                      -20-
<PAGE>

     Certain types of business acquisition transactions may be completed without
any   requirement   that  the  Company  first  submit  the  transaction  to  the
stockholders  for  their  approval.  In the event the  proposed  transaction  is
structured in such a fashion that stockholder approval is not required,  holders
of the  Company's  securities  (other  than  principal  stockholders  holding  a
controlling  interest)  should not  anticipate  that they will be provided  with
financial  statements or any other  documentation prior to the completion of the
transaction.   Other  types  of  transactions  require  prior  approval  of  the
stockholders.

     In the  event a  proposed  business  combination  or  business  acquisition
transaction is structured in such a fashion that prior  stockholder  approval is
necessary,  the  Company  will be  required  to  prepare a Proxy or  Information
Statement describing the proposed  transaction,  file it with the Securities and
Exchange  Commission  for  review  and  approval,  and  mail a copy of it to all
Company  stockholders  prior to holding a  stockholders  meeting for purposes of
voting on the  proposal.  Minority  shareholders  that do not vote in favor of a
proposed  transaction  may then have the right,  in the event the transaction is
approved  by  the  required  number  of  stockholders,   to  exercise  statutory
dissenter's rights and elect to be paid the fair value of their shares.

     The analysis of business  opportunities  will be undertaken by or under the
supervision  of  the  Company's  officers  and  directors,   none  of  whom  are
professional  business  analysts.  Although there are no current plans to do so,
Company   management  might  hire  an  outside   consultant  to  assist  in  the
investigation and selection of business opportunities,  and might pay a finder's
fee.  Since  Company  management  has  no  current  plans  to  use  any  outside
consultants or advisors to assist in the investigation and selection of business
opportunities,  no policies have been adopted  regarding use of such consultants
or advisors,  the criteria to be used in selecting such consultants or advisors,
the  services to be provided,  the term of service,  or the total amount of fees
that may be paid.  However,  because of the limited resources of the Company, it
is likely that any such fee the Company agrees to pay would be paid in stock and
not in cash.

     Otherwise,   in  analyzing   potential  business   opportunities,   Company
management anticipates that it will consider,  among other things, the following
factors:

     o    Potential for growth and  profitability  indicated by new  technology,
          anticipated market expansion, or new products;

     o    The Company's  perception of how any particular  business  opportunity
          will be  received by the  investment  community  and by the  Company's
          stockholders;

     o    Whether,  following the business combination,  the financial condition
          of the  business  opportunity  would be, or would  have a  significant
          prospect in the foreseeable  future of becoming,  sufficient to enable
          the securities of the Company to qualify for listing on an exchange or
          on a national automated  securities  quotation system, such as NASDAQ,


                                      -21-
<PAGE>

          so as to permit the trading of such  securities  to be exempt from the
          requirements  of Rule 15g-9  adopted by the  Securities  and  Exchange
          Commission.

     o    Capital  requirements and anticipated  availability of required funds,
          to be provided by the Company or from operations,  through the sale of
          additional securities, through joint ventures or similar arrangements,
          or from other sources;

     o    The extent to which the business opportunity can be advanced;

     o    Competitive  position as compared to other  companies  of similar size
          and  experience  within  the  industry  segment  as well as within the
          industry as a whole;

     o    Strength and diversity of existing management or management  prospects
          that are scheduled for recruitment;

     o    The cost of  participation by the Company as compared to the perceived
          tangible and intangible values and potential; and

     o    The accessibility of required  management  expertise,  personnel,  raw
          materials,  services,  professional  assistance,  and  other  required
          items.

     No one of the factors  described above will be controlling in the selection
of a business  opportunity,  and management  will attempt to analyze all factors
appropriate to each  opportunity and make a determination  based upon reasonable
investigative  measures  and  available  data.  Potentially  available  business
opportunities  may occur in many  different  industries and at various stages of
development,  all of which will make the task of comparative  investigation  and
analysis  of  such  business  opportunities  extremely  difficult  and  complex.
Potential  investors  must  recognize  that,  because of the  Company's  limited
capital  available for  investigation  and  management's  limited  experience in
business analysis,  the Company may not discover or adequately  evaluate adverse
facts about the opportunity to be acquired.

     The  Company is unable to  predict  when it may  participate  in a business
opportunity.  It expects,  however,  that the analysis of specific proposals and
the selection of a business opportunity may take several months or more.

     Prior to making a decision to  participate in a business  opportunity,  the
Company  will  generally  request  that it be provided  with  written  materials
regarding the business  opportunity  containing as much relevant  information as
possible,  including,  but not  limited  to,  such  items  as a  description  of
products,   services  and  Company  history;   management   resumes;   financial
information; available projections, with related assumptions upon which they are
based; an explanation of proprietary products and services; evidence of existing
patents,  trademarks,  or service marks, or rights thereto; present and proposed
forms of compensation to management;  a description of transactions between such
Company and its affiliates during the relevant periods; a description of present
and required  facilities;,  an analysis of risks and competitive  conditions;  a


                                      -22-
<PAGE>

financial  plan  of  operation  and  estimated  capital  requirements;   audited
financial  statements,  or  if  they  are  not  available,  unaudited  financial
statements, together with reasonable assurance that audited financial statements
would be able to be produced within a reasonable period of time not to exceed 60
days following completion of a merger or acquisition transaction; and the like.

     As part of the Company's  investigation,  the Company's  executive officers
and directors may meet personally  with management and key personnel,  may visit
and inspect material facilities,  obtain independent analysis or verification of
certain information provided,  check references of management and key personnel,
and take other reasonable investigative measures, to the extent of the Company's
limited financial resources and management expertise.

     It is  possible  that the range of  business  opportunities  that  might be
available  for  consideration  by the Company  could be limited by the impact of
Securities and Exchange  Commission  regulations  regarding purchase and sale of
penny stocks. The regulations would affect, and possibly impair, any market that
might  develop in the Company's  securities  until such time as they qualify for
listing  on  NASDAQ  or on  an  exchange  which  would  make  them  exempt  from
applicability of the penny stock  regulations.

     Company  management  believes  that various  types of  potential  merger or
acquisition  candidates might find a business combination with the Company to be
attractive.  These include  acquisition  candidates  desiring to create a public
market for their shares in order to enhance liquidity for current  stockholders,
acquisition  candidates  which have long-term  plans for raising capital through
public sale of  securities  and believe that the possible  prior  existence of a
public  market  for  their  securities  would  be  beneficial,  and  acquisition
candidates  which  plan  to  acquire   additional  assets  through  issuance  of
securities rather than for cash, and believe that the possibility of development
of a public market for their  securities  will be of assistance in that process.
Acquisition  candidates,  which have a need for an immediate cash infusion,  are
not likely to find a potential  business  combination  with the Company to be an
attractive alternative.

     (2)  Form of Acquisition

     It is impossible to predict the manner in which the Company may participate
in a business opportunity.  Specific business  opportunities will be reviewed as
well as the respective needs and desires of the Company and the promoters of the
opportunity  and,  upon the basis of the  review  and the  relative  negotiating
strength of the Company and such promoters, the legal structure or method deemed
by management to be suitable will be selected.  Such structure may include,  but
is not limited to leases, purchase and sale agreements, licenses, joint ventures
and other contractual  arrangements.  The Company may act directly or indirectly
through an interest in a partnership, corporation or other form of organization.
Implementing   such   structure  may  require  the  merger,   consolidation   or
reorganization  of the  Company  with other  corporations  or forms of  business
organization.  In  addition,  the present  management  and  stockholders  of the
Company  most likely will not have  control of a majority of the voting stock of


                                      -23-
<PAGE>

the Company following a merger or reorganization  transaction. As part of such a
transaction,  the Company's  existing directors may resign and new directors may
be appointed without any vote by stockholders.

     It is likely that the Company will acquire its  participation in a business
opportunity  through the  issuance of Common  Stock or other  securities  of the
Company.  Although the terms of any such  transaction  cannot be  predicted,  it
should be noted that in  certain  circumstances  the  criteria  for  determining
whether or not an acquisition is a so-called B tax free reorganization under the
Internal  Revenue  Code of 1986 as  amended,  depends  upon the  issuance to the
stockholders of the acquired  Company of a controlling  interest  (i.e.,  80% or
more) of the common stock of the combined  entities  immediately  following  the
reorganization.  If a transaction  were  structured  to take  advantage of these
provisions  rather than other a tax free provisions  provided under the Internal
Revenue Code, the Company's current  stockholders  would retain in the aggregate
20% or less of the total  issued and  outstanding  shares.  This could result in
substantial  additional dilution in the equity of those who were stockholders of
the Company prior to such reorganization. Any such issuance of additional shares
might also be done simultaneously with a sale or transfer of shares representing
a  controlling  interest in the Company by the current  officers,  directors and
principal stockholders.

     It is  anticipated  that any new  securities  issued in any  reorganization
would be issued in reliance upon one or more exemptions from registration  under
applicable  federal and state securities laws to the extent that such exemptions
are available.  In some  circumstances,  however, as a negotiated element of the
transaction,  the Company may agree to register  such  securities  either at the
time the  transaction is  consummated  or under certain  conditions at specified
times thereafter.  The issuance of substantial  additional  securities and their
potential  sale into any  trading  market  that might  develop in the  Company's
securities may have a depressive effect upon such market.

     The  Company  will  participate  in a business  opportunity  only after the
negotiation  and  execution of a written  agreement.  Although the terms of such
agreement  cannot  be  predicted,  generally  such an  agreement  would  require
specific  representations and warranties by all of the parties thereto,  specify
certain events of default,  detail the terms of closing and the conditions which
must be satisfied by each of the parties thereto prior to such closing,  outline
the manner of bearing costs if the transaction is not closed, set forth remedies
upon default, and include miscellaneous other terms.

     As a general matter, the Company  anticipates that it, and/or its principal
stockholders will enter into a letter of intent with the management,  principals
or owners  of a  prospective  business  opportunity  prior to  signing a binding
agreement.  Such a letter  of intent  will set  forth the terms of the  proposed
acquisition but will not bind any of the parties to consummate the  transaction.
Execution of a letter of intent will by no means indicate that  consummation  of
an acquisition is probable.  Neither the Company nor any of the other parties to
the letter of intent  will be bound to  consummate  the  acquisition  unless and
until a definitive  agreement is executed.  Even after a definitive agreement is
executed,  it is possible that the acquisition  would not be consummated  should
any party elect to exercise any right  provided in the agreement to terminate it
on specific grounds.


                                      -24-
<PAGE>

     It is anticipated that the investigation of specific business opportunities
and the negotiation,  drafting and execution of relevant agreements,  disclosure
documents and other  instruments  will require  substantial  management time and
attention and  substantial  costs for  accountants,  attorneys and others.  If a
decision is made not to  participate  in a specific  business  opportunity,  the
costs incurred in the related investigation would not be recoverable.  Moreover,
because many providers of goods and services require compensation at the time or
soon after the goods and services are provided,  the inability of the Company to
pay until an  indeterminate  future time may make it impossible to produce goods
and services.

     (3)  Investment Company Act and Other Regulation

     The  Company  may  participate  in a business  opportunity  by  purchasing,
trading or selling  the  securities  of such  business.  The  Company  does not,
however,  intend to  engage  primarily  in such  activities.  Specifically,  the
Company intends to conduct its activities so as to avoid being  classified as an
investment  Company  under the  Investment  Company Act of 1940 (the  Investment
Act),  and  therefore  to  avoid  application  of  the  costly  and  restrictive
registration  and other  provisions of the Investment  Act, and the  regulations
promulgated thereunder.

     The  Company's  plan  of  business  may  involve  changes  in  its  capital
structure,  management,  control and business,  especially if it consummates the
reorganization  as  discussed  above.  Each of these areas is  regulated  by the
Investment Act, in order to protect purchasers of investment Company securities.
Since the Company will not register as an investment Company,  stockholders will
not be afforded these protections.

     (d) Results of Operations, Liquidity and Capital Resources: The Company has
had no significant  operations during the last fiscal year and, accordingly,  is
fully dependent either future sales of securities or upon its current management
and, or advances or loans from significant stockholders or corporate officers to
provide  sufficient  working  capital to preserve the integrity of the corporate
entity.

     There is no assurance  that the Company  will be able to obtain  additional
funding  through the sales of additional  securities  or, that such funding,  if
available,  will be obtained on terms favorable to or affordable by the Company.
It  is  the  intent  of  management  and  significant  stockholders  to  provide
sufficient  working  capital  necessary to support and preserve the integrity of
the  corporate  entity.  However,  there  is  no  legal  obligation  for  either
management or significant stockholders to provide additional future funding.

     During the  quarter  ended  September  30,  2006,  the  Company  incurred a
comprehensive  net loss of approximately  $17,402 related to various general and
administrative  costs incurred in the support of the corporate entity and making
required periodic reports to the U. S. Securities and Exchange Commission.

     We will need to raise  capital in order to commence our  proposed  business
operations.  No assurance can be given that we will be able to raise  sufficient


                                      -25-
<PAGE>

capital to implement any proposed  business  operations.  We have not identified
any specific future financing sources. In the future, our efforts to finance the
Company  may result in the  issuance  of equity and debt  instruments.  This and
other  future  financing  activity,  if  any,  may  result  in the  dilution  of
shareholder  equity.  We expect to incur  financial  losses for the  foreseeable
future.

Acquisition or Disposition of Plant and Equipment

We do not anticipate the acquisition or disposition of any significant property,
plant or equipment during the next 12 months.

From our inception  through the period ended  September 30, 2006, we have relied
on the  services of outside  consultants  for services  and  currently  have one
part-time employee. In order for us to attract and retain quality personnel,  we
anticipate  we will have to offer  competitive  salaries  to  future  employees.
Inflation

The effect of  inflation  on our  operating  results  was not  significant.  Our
operations  are located in North America and there are no seasonal  aspects that
would  have  a  material  effect  on  our  financial  condition  or  results  of
operations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3.   Controls and Procedures.

(a)  Evaluation of Disclosure Controls and Procedures.

As of the end of the  reporting  period,  September  30, 2006, we carried out an
evaluation,  under the supervision and with the participation of our management,
including  the  Company's   Chairman  and  Chief   Executive   Officer/Principal
Accounting  Officer,  of the  effectiveness  of the design and  operation of our
disclosure  controls and procedures pursuant to Rule 13a-15(e) of the Securities
Exchange  Act of 1934  (the  "Exchange  Act"),  which  disclosure  controls  and
procedures are designed to insure that information required to be disclosed by a
company  in the  reports  that it files  under  the  Exchange  Act is  recorded,
processed, summarized and reported within required time periods specified by the
SEC's rules and forms.  Based upon that  evaluation,  the Chairman and the Chief
Financial  Officer  concluded  that our  disclosure  controls and procedures are
effective  in timely  alerting  them to  material  information  relating  to the
Company  required to be included in the  Company's  period SEC filings.  We were
late filing our annual  report on Form  10-KSB for the fiscal year ending  March
31, 2006 and our quarterly  report on Form 10-QSB for the periods ending June 30
and September 30, 2006. We have been unable to timely file our periodic  reports
due  to  the  lack  of  sufficient  money  to  pay  our  independent  certifying
accountants.

(b)  Changes in Internal Control.

Subsequent to the date of such evaluation as described in  subparagraph(a)above,
there were no changes  in our  internal  controls  or other  factors  that could


                                      -26-
<PAGE>

significantly affect these controls, including any corrective action with regard
to significant deficiencies and material weaknesses.

(c)  Limitations.

Our  management,   including  our  Principal  Executive  Officer  and  Principal
Financial  Officer,  does not expect  that our  disclosure  controls or internal
controls over  financial  reporting  will prevent all errors or all instances of
fraud.  However,  we believe that our  disclosure  controls and  procedures  are
designed to provide reasonable assurance of achieving this objective.  A control
system,  no matter how well designed and operated,  can provide only reasonable,
not  absolute,  assurance  that the  control  system's  objectives  will be met.
Further,  the design of a control  system  must  reflect the fact that there are
resource  constraints,  and the benefits of controls must be considered relative
to their costs.  Because of the inherent  limitations in all control systems, no
evaluation of controls can provide  absolute  assurance  that all control issues
and instances of fraud,  if any,  within our company have been  detected.  These
inherent limitations include the realities that judgments in decision-making can
be faulty,  and that  breakdowns  can occur  because of simple error or mistake.
Controls can also be  circumvented  by the individual  acts of some persons,  by
collusion of two or more people, or by management override of the controls.  The
design of any system of controls is based in part upon certain assumptions about
the likelihood of future events, and any design may not succeed in achieving its
stated goals under all  potential  future  conditions.  Over time,  controls may
become  inadequate  because of changes in  conditions  or  deterioration  in the
degree of  compliance  with  policies  or  procedures.  Because of the  inherent
limitation of a  cost-effective  control system,  misstatements  due to error or
fraud may occur and not be detected.

                            PART II-OTHER INFORMATION

Item 1.   Legal Proceedings.

     The Company is not a party to any pending material legal proceedings.


Item 2.   Unregistered Sale of Equity Securities and Use of Proceeds.

     On August 8, 2006,  the Company issued  74,000,000  common shares which are
held in escrow  and  associated  with the  Securities  Exchange  Agreement  with
MediPri Limited,  Primeedical  International,  Ltd. and Medical Monitors Limited
and the Company.  The Agreement has not been  performed and the shares remain in
escrow.

Item 3.   Defaults upon Senior Securities.  None.

Item 4.   Submission of Matters to a Vote of Security Holders.

     No matter was  submitted  to a vote of the  security  holders,  through the
solicitation  of proxies or  otherwise,  during the  quarter of the fiscal  year
covered by this report.


                                      -27-
<PAGE>

Item 5.   Other Information.

     None.

Item 6.   Exhibits

     (a)  Exhibits:


     31   Chief  Executive   Officer-Section   302  Certification   pursuant  to
          Sarbanes-Oxley Act.
     32   Chief  Executive   Officer-Section   906  Certification   pursuant  to
          Sarbanes-Oxley Act.

                                   SIGNATURES

     In accordance  with the  requirements  of the Exchange Act, the  registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Dated: December 13, 2006.


GLOBAL IMMUNE TECHNOLOGIES, INC.




By: /s/ Donald Perks
    ---------------------
    Donald Perks
    Title: President, CEO, CFO